Cell-specific targeting by heterobivalent ligands.

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Current cancer therapies rely on targeting single overexpressed proteins or metabolic differences.
• A need exists for more specific and effective cell-targeting strategies in cancer treatment.

Purpose of the Study:

• To develop and validate a novel "receptor combination approach" for precise cell targeting.
• To demonstrate the feasibility of using heteromultivalent ligands (htBVLs) to cross-link multiple cell-surface receptors.

Main Methods:

• Synthesized heterobivalent ligands (htBVLs) by conjugating melanocortin peptide analogues and cholecystokinin peptide analogues.
• Utilized computational modeling to determine optimal linker length (20-50 Å) for simultaneous receptor binding.
• Analyzed ligand binding affinity and specificity on cells expressing human Melanocortin-4 receptor and Cholecystokinin-2 receptor.

Main Results:

• Engineered htBVLs demonstrated high avidity and specificity for cells co-expressing target receptors.
• Achieved up to a 24-fold enhancement in binding affinity through bivalent binding compared to monovalent binding.
• Showcased up to 50-fold higher affinity with htBVLs compared to a monomeric cholecystokinin ligand.

Conclusions:

• The receptor combination approach is validated as a viable strategy for specific cell targeting.
• Heteromultivalent ligands effectively cross-link functionally unrelated receptors with high precision.
• This approach offers new avenues for in vivo cell targeting in cancer therapy and imaging.